Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | HTR1D | P28221 | 12/20 | 0.48 |
| ▸ | HTR1B | P28222 | 12/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR1F | P30939 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2934570 | 0.79 | KDM4E (0.60) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL2935082 | 0.78 | HTR1D (0.61) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL28794345 | 0.78 | HTR1D (0.55) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL7539016 | 0.77 | HTR1D (0.70) | HTR1DHTR1BHTR1AHTR1FMAPT | |
| SCHEMBL25072243 | 0.76 | MTNR1A (0.65) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL5363538 | 0.74 | CYP1A2 (0.60) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL7478845 | 0.74 | HTR1D (0.70) | HTR1DHTR1BHTR1AHTR1FMAPT | |
| SCHEMBL4799796 | 0.74 | MAPT (0.65) | HTR1DHTR1BMTNR1AMTNR1BHTR1A | |
| SCHEMBL9268388 | 0.74 | KDM4E (0.61) | KDM4EATMHTR1DHTR1BNOS3 | |
| SCHEMBL7477707 | 0.73 | HTR1D (0.64) | HTR1DHTR1BNOS1HTR1AHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| EP-2220075-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | Neuraxon, INC. (CA) | 2010-08-25 | — | — | EP | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2009062319-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | KDM4E 2304/4885ATM 3514/4885HTR1D 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.